BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25501013)

  • 1. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.
    Chou A; Fraser S; Toon CW; Clarkson A; Sioson L; Farzin M; Cussigh C; Aniss A; O'Neill C; Watson N; Clifton-Bligh RJ; Learoyd DL; Robinson BG; Selinger CI; Delbridge LW; Sidhu SB; O'Toole SA; Sywak M; Gill AJ
    Am J Surg Pathol; 2015 May; 39(5):652-9. PubMed ID: 25501013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
    Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
    J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.
    Park G; Kim TH; Lee HO; Lim JA; Won JK; Min HS; Lee KE; Park DJ; Park YJ; Park WY
    Endocr Relat Cancer; 2015 Feb; 22(1):55-63. PubMed ID: 25527510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.
    Lee YS; Kim Y; Jeon S; Bae JS; Jung SL; Jung CK
    Int J Clin Exp Pathol; 2015; 8(7):7988-97. PubMed ID: 26339365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma.
    Chou A; Qiu MR; Crayton H; Wang B; Ahadi MS; Turchini J; Clarkson A; Sioson L; Sheen A; Singh N; Clifton-Bligh RJ; Robinson BG; Gild ML; Tsang V; Leong D; Sidhu SB; Sywak M; Delbridge L; Aniss A; Wright D; Graf N; Kumar A; Rathi V; Benitez-Aguirre P; Glover AR; Gill AJ
    Mod Pathol; 2023 Dec; 36(12):100329. PubMed ID: 37716505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors.
    Hamatani K; Mukai M; Takahashi K; Hayashi Y; Nakachi K; Kusunoki Y
    Thyroid; 2012 Nov; 22(11):1153-9. PubMed ID: 23050789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
    Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bastos AU; de Jesus AC; Cerutti JM
    Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
    Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
    Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of chromosomal translocations involving ALK gene in anaplastic large cell lymphoma by fluorescence in-situ hybridization and its clinical significance].
    Huang WT; Li XQ; Yao XH; Lu YM; Sheng WQ; Lu HF; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):371-5. PubMed ID: 22932403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
    Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
    Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.